Disclosed are: an anti-human α9 integrin antibody, more specifically a monoclonal antibody, a chimeric antibody, a humanized antibody or a human antibody which can recognize human α9 integrin specifically; a hybridoma cell which can produce the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the anti-human α9 integrin antibody; a method for the screening of a compound capable of inhibiting the activity of human α9 integrin; and others.